Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.

Antimicrobial Agents and Chemotherapy
Rima K AcostaKirsten L White

Abstract

In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies. These mutations did not affect treatment outcomes. Resistance analyses in 13 virologic failures found no emergent resistance to study drugs.

References

Jan 10, 2003·Nucleic Acids Research·Soo-Yon RheeRobert W Shafer
Oct 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher B HurtJoseph J Eron
Nov 8, 2013·The New England Journal of Medicine·Sharon L WalmsleyUNKNOWN SINGLE Investigators
Aug 28, 2015·The Journal of Antimicrobial Chemotherapy·Tomas DoyleUNKNOWN CORONET Study Group
Dec 19, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Babafemi O TaiwoRoy M Gulick
Aug 19, 2018·Retrovirology·Maureen OliveiraUNKNOWN Montreal Primary HIV (PHI) Cohort Study Group

❮ Previous
Next ❯

Citations

Aug 30, 2020·Drugs·Kimberly K ScarsiCourtney V Fletcher
Sep 16, 2020·The Journal of Antimicrobial Chemotherapy·M CasadellàUNKNOWN INSTINCT Study Group
Oct 17, 2019·The Journal of Antimicrobial Chemotherapy·Philip L TzouUNKNOWN WHO HIVResNet Working Groups
Jul 31, 2020·The Journal of Antimicrobial Chemotherapy·Jean L MbisaAnna Maria Geretti
Feb 13, 2021·Viruses·Steven J SmithStephen H Hughes
Oct 15, 2020·JAMA : the Journal of the American Medical Association·Michael S SaagPaul A Volberding

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
Nicolas A MargotChristian Callebaut
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
J ParrondoS Cenoz-Gomis
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
G PialouxC Aubin
Journal of the American Pharmacists Association : JAPhA
Daniel A Hussar, Rachel C Boardman
© 2022 Meta ULC. All rights reserved